Core Structure-Activity Relationship Studies of 5,7,20-O-Trimethylsilybins in Prostate Cancer Cell Models

Area of Science:

• Natural Products Chemistry
• Medicinal Chemistry
• Cancer Biology

Background:

• Silibinin, derived from milk thistle, shows potential for prostate cancer treatment but has limitations.
• Previous research identified 5,7,20-O-trimethylsilybins as promising compounds for suppressing androgen receptor (AR)-positive prostate cancer cells.

Purpose of the Study:

• To investigate the structure-activity relationships of 5,7,20-O-trimethylsilybin core structures against AR-positive and AR-negative prostate cancer cells.
• To evaluate the antiproliferative potency of optically enriched 5,7,20-O-trimethylsilybin derivatives.

Main Methods:

• Compared antiproliferative activities of four core structures (flavanonol, flavone, chalcone, precursor) of 5,7,20-O-trimethylsilybin derivatives.
• Assessed activity against AR-positive (LNCaP) and AR-negative (PC-3, DU145) prostate cancer cell lines.
• Investigated stereoisomer differences between silybin A and silybin B series.

Main Results:

• 5,7,20-O-trimethylsilybins demonstrated the most promising scaffold for selectively suppressing AR-positive LNCaP cell proliferation.
• Optically enriched (10R,11R) derivatives (silybin A series) were more potent than (10S,11S) derivatives (silybin B series).
• Selective suppression of AR-positive prostate cancer cells was observed.

Conclusions:

• 5,7,20-O-trimethylsilybins represent a promising scaffold for developing novel prostate cancer therapeutics.
• Stereochemistry plays a crucial role in the antiproliferative activity of these compounds.
• Further development of silybin A derivatives could lead to effective treatments for castration-resistant prostate cancer.